IAGG’s Landmark Research Breakthroughs in Alzheimer’s and Dementia Prevention

Dementia affects more than 55 million people worldwide, with Alzheimer’s disease accounting for 60 to 70 percent of all cases. By 2050, that number is projected to nearly triple — a slow-moving public health crisis touching every country, every culture, and every generation. In the sustained effort to understand, prevent, and ultimately defeat this disease, few organizations have had as consistent and far-reaching an influence as the International Association of Gerontology and Geriatrics (IAGG).

Established in 1950, the International Association of Gerontology and Geriatrics brings together more than 70 national and regional gerontological societies, uniting researchers, clinicians, educators, and policymakers across more than 60 countries. Through its World Congresses, scientific task forces, regional affiliate networks, and sustained partnerships with the World Health Organization and the United Nations, IAGG has consistently placed dementia prevention at the center of the global healthy aging research agenda.

This article examines the landmark research breakthroughs in Alzheimer’s and dementia prevention that have been advanced, endorsed, and catalyzed through the International Association of Gerontology and Geriatrics IAGG platform — and what they mean for the millions of families living in the shadow of cognitive decline.

The Scale of the Problem: Why Prevention Research Is Urgent

According to the World Health Organization, dementia costs the global economy approximately $1.3 trillion each year — a figure that will only grow as populations age. Alzheimer’s disease is now among the leading causes of death in high-income countries, and its incidence is rising sharply in low- and middle-income nations where healthcare systems are already strained.

For much of the twentieth century, the scientific community treated dementia as an inevitable consequence of aging — a biological destiny that medicine could delay but not prevent. The research of the last two decades has challenged that assumption fundamentally. We now know that a meaningful proportion of dementia cases is, in principle, preventable. That shift did not emerge in isolation. It came from the kind of coordinated, cross-disciplinary, multinational effort that the International Association of Gerontology and Geriatrics was built to enable.

Modifiable Risk Factors: Rewriting the Prevention Narrative

One of the most consequential contributions to dementia science in recent decades has been the systematic identification and quantification of modifiable risk factors — lifestyle and health variables that, if addressed, can meaningfully reduce an individual’s probability of developing Alzheimer’s or another dementia syndrome.

The Lancet Commission on Dementia Prevention, Intervention, and Care — whose findings have been debated at multiple IAGG forums — has been central to this work. Its analysis, first published in 2017 and updated in 2020 and 2024, concluded that up to 45 percent of dementia cases could potentially be prevented or delayed by addressing key risk factors across the life course.

These evidence-based factors, now widely accepted across the gerontological research community, include:

• Low educational attainment in early life
• Untreated hearing loss in midlife
• Traumatic brain injury
• Hypertension and cardiovascular disease
• Excessive alcohol consumption
• Obesity
• Smoking
• Depression
• Social isolation and loneliness
• Physical inactivity
• Exposure to air pollution
• Uncontrolled type 2 diabetes

The practical implication is significant: a substantial share of Alzheimer’s and dementia cases is not simply determined by genetics or aging — it is shaped by choices, environments, and social conditions that can change. IAGG has been instrumental in translating this evidence into global advocacy, pressing health ministries and international bodies to embed dementia prevention into public health policy rather than treating it solely as a clinical issue.

The WorldWideFINGERS Initiative: A Global Leap in Multidomain Prevention

Perhaps the single most significant research milestone in dementia prevention in the last decade has been the demonstration that multidomain lifestyle interventions — structured programs targeting several risk factors at once — can meaningfully protect cognitive function in at-risk older adults.

The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability, known internationally as the FINGER trial, was a landmark randomized controlled study that showed, for the first time in a large-scale rigorous design, that a comprehensive program combining nutritional guidance, physical exercise, cognitive training, and cardiovascular risk management could slow cognitive decline in older adults at elevated risk. Its results, published in The Lancet in 2015, sent a clear scientific signal: prevention is not only theoretically possible — it is measurable, replicable, and worth scaling.

Building directly on these findings, the WorldWideFINGERS network was launched at the IAGG World Congress in San Francisco, as an international consortium committed to replicating and adapting the FINGER model across diverse global populations. Supported through the International Association of Gerontology and Geriatrics framework, this growing network now spans dozens of countries across Europe, Asia, the Americas, Africa, and Oceania. Each participating trial adapts the core multidomain intervention to its population’s cultural context, dietary traditions, healthcare infrastructure, and health literacy landscape.

The scientific value of WorldWideFINGERS is twofold. It generates a richer evidence base by testing whether FINGER’s findings hold across different ethnicities, socioeconomic profiles, and care systems. And it creates a durable global infrastructure for dementia prevention research that no single nation could build alone — precisely the kind of infrastructure that IAGG was created to sustain.

Biomarker Research: The Science of Early Detection

Prevention is most effective when it can begin before symptoms appear. A parallel revolution in biomarker science has transformed the field’s capacity to identify individuals at elevated risk of Alzheimer’s years — sometimes decades — before a clinical diagnosis would be possible through conventional assessment alone.

Key Advances in Alzheimer’s Biomarkers

The following table summarizes the major biomarker categories that have become central to early detection and prevention research, each of which has received sustained attention at IAGG World Congresses and in publications by IAGG-affiliated researchers:

The development of blood-based biomarkers has been particularly transformative. Until recently, confirming Alzheimer’s pathology required either expensive brain imaging or an invasive lumbar puncture — neither scalable for population-level screening. Blood tests for phosphorylated tau proteins, now demonstrating accuracy comparable to CSF analysis, have the potential to bring early detection within reach for health systems worldwide, including lower-resource settings where IAGG has increasingly focused its advocacy efforts.

From Detection to Prevention: Connecting the Dots

Biomarker science matters for prevention because it allows researchers to enroll high-risk individuals in trials long before symptoms emerge — the window when intervention is most likely to be effective. Several major ongoing trials now use amyloid or tau biomarker status as a central inclusion criterion, a design approach championed by IAGG-affiliated scientists as a model for next-generation prevention research.

Pharmacological Progress: The First Disease-Modifying Treatments

For many years, pharmacological research in Alzheimer’s was defined more by failure than by progress, with hundreds of drug candidates falling short in late-stage trials. The recent regulatory approvals of lecanemab and donanemab — two anti-amyloid monoclonal antibodies — represent a genuine turning point, even as the scientific community continues to assess the magnitude of their clinical benefit and the practical challenges of their administration.

These approvals go beyond therapeutic effect: they validate the amyloid cascade hypothesis — that accumulation of amyloid-beta in the brain is a central driver of Alzheimer’s disease. By demonstrating that clearing amyloid can slow cognitive decline, these trials open the door to combination strategies and earlier pharmacological intervention in pre-symptomatic individuals, particularly when paired with the biomarker tools now coming into clinical reach.

The International Association of Gerontology and Geriatrics has consistently provided a platform for nuanced, evidence-based discussion of pharmacological approaches — ensuring that both the genuine promise and the real-world limitations of new treatments are examined with scientific rigor, and that the conversation about drugs does not crowd out the equally important work on lifestyle-based prevention.

Cognitive Reserve and the Life Course Perspective

Among the most productive contributions of gerontological research to dementia science is the concept of cognitive reserve — the brain’s capacity to cope with accumulating pathology by drawing on neural networks built up across a lifetime. Research consistently shows that individuals with higher educational attainment, greater intellectual engagement, richer social lives, and stronger physical fitness carry a measurable protective advantage against dementia, even when brain pathology is objectively present.

This life course perspective — recognizing that the seeds of dementia risk are planted and the foundations of brain resilience are built decades before any symptom appears — has been central to the advocacy work of The International Association of Gerontology and Geriatrics. IAGG has been clear and consistent: dementia prevention cannot begin at the age of 65. Investment in education, mental health, social participation, and cardiovascular health in midlife and early adulthood is, in effect, investment in the brain health of the next generation of older adults.

The lifestyle factors with the strongest evidence for cognitive protection include:

• Regular physical activity: Aerobic exercise reduces hippocampal atrophy, improves cerebral blood flow, and is consistently associated with a 30–35% reduction in dementia risk.
• Cognitive engagement: Lifelong learning and mentally stimulating leisure — reading, music, problem-solving — are linked to delayed cognitive decline across multiple cohort studies.
• Social connection: Social isolation now ranks as a dementia risk factor of comparable magnitude to smoking, with significant implications for post-pandemic public health.
• Dietary patterns: The Mediterranean and MIND diets, rich in vegetables, legumes, whole grains, and fish, are associated with slower cognitive aging and reduced Alzheimer’s incidence.
• Sleep quality: Poor sleep and untreated sleep apnea are linked to accelerated amyloid accumulation, making sleep health an important and highly modifiable prevention target.

IAGG’s Global Advocacy: From Research to Policy

Research breakthroughs only change lives when the evidence is translated into policy and practice. IAGG has played an active and sustained role in ensuring that the science of dementia prevention reaches governments, health systems, and communities on every continent.

The organization has contributed to the WHO’s Global Dementia Observatory, advocated for the inclusion of brain health within national aging strategies, and used its World Congresses as high-visibility platforms for disseminating evidence across disciplines and borders. Regional affiliates — including IAGG-ER in Europe and PAGU across the Americas — amplify this advocacy in ways tailored to their regions’ specific health priorities and policy contexts.

IAGG has also consistently championed equity in dementia research. A growing body of evidence confirms that dementia disproportionately affects populations living with poverty, discrimination, and limited access to education and healthcare — groups significantly underrepresented in clinical trials. Closing that gap is both a scientific necessity and a moral imperative. Expanding the geographic, socioeconomic, and demographic diversity of dementia research is now an explicit institutional priority for International Association of Gerontology and Geriatrics IAGG and its global member societies.

The Road Ahead: Emerging Frontiers in Dementia Prevention

The next decade promises to be among the most consequential in the history of Alzheimer’s and dementia research. Several major developments are already moving from laboratory to practice:

• Population-level screening: Programs using blood-based biomarkers for pre-symptomatic risk identification are being piloted in multiple countries, with IAGG-affiliated researchers contributing to protocol design and ethical frameworks.
• Artificial intelligence in early detection: AI tools detecting subtle cognitive changes through speech analysis, eye-tracking, and digital behavior patterns offer a non-invasive, scalable frontier for affordable screening worldwide.
• New biological targets: Trials targeting neuroinflammation, metabolic dysfunction, and the gut-brain axis are expanding the research landscape well beyond the amyloid-tau axis that has dominated the field for three decades.
• Precision prevention: Advances in genomics and multi-omics profiling are enabling risk stratification by individual biological profile, laying the groundwork for personalized prevention rather than universal recommendations.

Through its scientific congresses, expert working groups, and global research networks, The International Association of Gerontology and Geriatrics will remain at the center of this evolving conversation — connecting the scientists, clinicians, policymakers, and community advocates whose collaboration is essential to converting these advances into real-world change.

Conclusion: A Turning Point Built on Collective Science

The story of dementia prevention research is, at its heart, a story about what becomes possible when scientists stop working in isolation and start working together. The breakthroughs of the last two decades — from the mapping of modifiable risk factors and the FINGER trial’s proof of concept, to blood-based biomarkers and the first disease-modifying drug approvals — have each depended on international collaboration, open data sharing, and the cross-disciplinary dialogue that IAGG was founded to cultivate.

The International Association of
Gerontology and Geriatrics functions as connective tissue within the global aging research enterprise — amplifying discoveries, accelerating their translation into practice, and ensuring that the priorities of older adults remain central to the research agenda. That mission has never been more important.

We have not yet reached the end of the Alzheimer’s story. But for the first time in the history of this disease, prevention is not a distant aspiration — it is an emerging scientific reality. And through its networks, its advocacy, and its commitment to global collaboration, the International Association of Gerontology and Geriatrics stands at the forefront of making that reality accessible to every aging person on earth.